T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India, 2022-09-09 12:48 (1030 d 00:00 ago) – Posting: # 23282
Views: 4,598

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,684 registered users;
26 visitors (0 registered, 26 guests [including 11 identified bots]).
Forum time: 12:49 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5